Published in Gene Therapy Weekly, December 15th, 2005
The data also support the safety and potential efficacy of its lead targeted PI3K kinase inhibitor SF1126 as a new approach to treating cancer, as well as the company's plans to advance SF1126 into clinical trials in 2006. The data were presented at the 17th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia, Pennsylvania.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly